Monoclonal Antibody Therapies Continue Rapid Growth in Cancer Market
The new study, "Monoclonal Antibodies in Cancer Therapy: Emerging Products and Markets," found that with expected product introductions and continuing clinical penetration, the now $3 to $4 billion industry, will approach almost $13 billion by 2008.
"Unlike other big-ticket drug areas, competition is limited in this market because of the very specific target each product is approved for," notes Melissa Elder, author of the report. "However, even if one area is being target well, such as Genentech in lymphoma, other areas, such as lung cancer, are considerably in need of attention. There is plenty of opportunity."
At least two (and as many as five) emerging monoclonal antibody-based cancer products will hit the market in 2005 according to the report which reviews over 120 products in currently in development. The study covers these emerging product and currently available treatments in eight oncology areas, projecting product launches, revenues, and competitive market positions of the major developers.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous